BIC

DRUG4 trials

Sponsors

Gilead Sciences, St. Joseph's Healthcare Hamilton

Conditions

HIV-1 InfectionHIV-1-infectionSuicidal Behavior

Phase 2

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02397694

Gilead SciencesHIV-1 Infection

Start: 2015-03-23End: 2019-02-27Updated: 2020-04-07

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

TerminatedNCT03472326

Gilead SciencesHIV-1-infection

Start: 2018-04-03End: 2019-12-09Updated: 2021-01-05

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

CompletedNCT04143594

Gilead SciencesHIV-1-infection

Start: 2019-11-22End: 2023-09-19Updated: 2024-10-02

Unknown Phase

Brief Intervention and Contact (BIC) Program

CompletedNCT03825354

St. Joseph's Healthcare HamiltonSuicidal Behavior

Start: 2019-04-01End: 2021-09-30Updated: 2022-02-01

Related Papers

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study.

2025-10-07

Recruitment rates, retention rates, and follow-up completion in a Brief Intervention and Contact trial for suicidal behavior: a feasibility study.

2025-04-161 citations

Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV

AIDS and Behavior2025-03-101 citations

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

2023-01-0173 citations

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.

Journal of Clinical Oncology2020-05-20

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

2017-02-1569 citations